3 October 2018 - As trade experts look deeper into what exactly Canada signed onto as part of the United States-Mexico-Canada Agreement, questions are arising about what the new trade deal will mean for drug costs, and whether or not Canada just tied its hands when it comes to trade diversification.
The trilateral deal will replace NAFTA once all three countries’ legislatures approve and ratify the wide-spanning agreement, which took 14 months of renegotiation.
The new deal includes a chapter that has raised the eyebrows of some trade experts, and critics of the federal Liberal government.
The opposition Conservatives are calling it a “Trump veto,” and it’s thrown into question how it could impact future trade deals Canada makes, specifically with China, given the trade threats and tariffs that U.S. President Donald Trump has levelled against the Asian nation.